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osting by EAbstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in the regulation
of low-density lipoprotein cholesterol (LDL-C) levels by virtue of its ability to target the LDL-
receptor. Mutations of PCSK9 result in either a decrease (i.e. gain of function mutations) or an
increase (i.e. loss of function mutations) in LDL receptor levels. For gain of function variants, this
translates into an increase in plasma concentrations of LDL-C and increased susceptibility to
cardiovascular disease. In contrast, loss of function variants substantially lower LDL-C levels
and cardiovascular disease incidence. Given that statins also increase PCSK9 expression, which
is counterproductive to their effect on LDL-receptor regulation, it is suggested that adding a
PCSK9 inhibitor might increase the LDL-C lowering efﬁciency of statin treatment. Peroxisome pro-
liferator-activated receptor agonists such as fenoﬁbrate repress PCSK9 expression. In vitro studies
show that co-administration of fenoﬁbrate with a statin counteracts statin-induced expression of
PCSK9, further increasing LDL-receptor activity. Clinically, this approach results in enhanced
LDL-C lowering efﬁciency of the statin, thereby supporting the functional relevance of combination
treatment with fenoﬁbrate and a statin. Finally, evidence that PCSK9 levels are also associated withsk in Communities study; ER,
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J.-C. Fruchart 5changes in plasma levels of glucose, triglycerides and high-density lipoprotein cholesterol suggests
that PCSK9 may be a potential target in patients with type 2 diabetes or metabolic syndrome. Such
an approach could impact the substantial residual cardiovascular risk that exists in statin-treated
patients.
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The discovery of proprotein convertase subtilisin/kexin type 9
(PCSK9), and subsequent recognition of its role in low-density
lipoprotein cholesterol (LDL-C) homeostasis [1–4], presents
new therapeutic possibilities. It has been postulated that
PCSK9 may have application as a potential target, based on
an understanding of its mode of activity in regulating degrada-
tion of the low-density lipoprotein receptor (LDL-R) [1]. Fur-
ther, PCSK9 expression is up-regulated by statins, which could
be counterproductive to their LDL-C lowering efﬁcacy [5]. Re-
cent experimental evidence suggesting that modulation of
PCSK9 expression by fenoﬁbrate, a peroxisome proliferator-
activated receptor alpha (PPARa) ligand, can amplify the
LDL-C lowering efﬁcacy of statins [6] is, therefore, intriguing,
and provides justiﬁcation for the functional relevance of com-
bination lipid-modifying therapy. Such an approach could
potentially impact the residual cardiovascular risk that exists
in statin-treated patients.
2. PCSK9 physiology
PCSK9 (also known as PC9 or Narc-1) is a 692-amino acid
serine protease encoded by the PCSK9 gene on chromosome
1p32.3. PCSK9 is a member of the proprotein convertase fam-
ily. These enzymes act as molecular scissors for the processing
of a range of precursor proteins including growth factors, neu-
ropeptides, receptors, enzymes and transcription factors.
PCSK9 is expressed in the liver and small intestine, but is
only released by the liver into the circulation [7,8]. It comprises
three domains: a N-terminal domain, a catalytic domain and a
carboxyl-terminal domain, together with a catalytic triad (Asp,
His and Ser residues), which is involved in substrate binding
and catalysis. PCSK9 is synthesized in the endoplasmic reticu-
lum (ER) as an inactive zymogene (Pro-PCSK9), which is then
transformed into its active form by autocatalytic cleavage of
the prodomain. This prodomain remains associated with the
catalytic domain thereby preventing protease activity, acting
as a chaperone permitting the mature protein to move from
the ER into the secretory pathway. In the plasma, PCSK9 is
secondarily metabolized by the proprotein convertases furin,
and to a lesser extent PC5/6A, to a truncated inactive form
[1,9].
3. PCSK9 and cholesterol metabolism
PCSK9 was originally implicated in liver regeneration [10].
However, interest in PCSK9 escalated when subsequent ﬁnd-
ings suggested a role in cholesterol metabolism.
Autosomal-dominant familial hypercholesterolemia (FH) is
characterized by markedly elevated LDL-C levels and prema-
ture atherosclerotic disease. The condition is caused by defects
in the LDL-R recycling pathway that impair the normaluptake and clearance of LDL by the liver. The most common
cause of FH is mutations in genes coding for the LDL-R,
although defects also occur in APOB (familial defective apoli-
poprotein B-100) [11]. However, in 2003, Abidafel et al. [12]
identiﬁed two missense PCSK9 mutations (S127R and
F216L) associated with autosomal dominant hypercholesterol-
emia. These ﬁndings, supported by additional genetic linkage
studies, established PCSK9 as a causal gene for familial auto-
somal-dominant hypercholesterolemia [13–16]. Recent evi-
dence also suggests that PCSK9 may act as a modiﬁer gene
in subjects with FH, due to the LDL-R mutation pCYS681X
[17]. Added to this, the transcriptional regulation of PCSK9
was shown to be dependent on cellular sterol status, mediated
via a regulatory element in the promoter region, which is the
primary binding sequence for the transcription factor
SREBP-2 (human sterol regulatory element binding protein
1a) [18,19].
Evidence indicates that PCSK9 post-translationally targets
the degradation of the LDL-R [1–4]. Although the molecular
mechanisms of this process are quite complex, it is thought
that the binding of PCSK9 to the LDL-R on the surface of
the cell leads to conformational changes, shifting the equilib-
rium to lysosomal-dependent degradation rather than recy-
cling LDL-R from the endosome back to the cell membrane
[1]. As PCSK9 enzymatic activity is not required, this suggests
that PCSK9 acts as a chaperone in promoting LDL-R degra-
dation [20]. Thus, the function of PCSK9 as a secreted factor is
physiologically signiﬁcant, as in targeting LDL-R degradation,
PCSK9 inﬂuences LDL-C levels.4. Factors inﬂuencing PCSK9 expression
In the normal population (without hypercholesterolemia),
plasma PCSK9 levels are around 90 ng/mL, slightly higher in
women than in men [21,22], especially in the postmenopausal
state [23]. Plasma levels have been positively correlated with
levels of total cholesterol, LDL-C [24,25] and triglycerides
[26], with these relationships also apparent in children and in
adolescents [22]. There are, however, discordant reports of a
gender effect with respect to the relationship with total and
LDL-C [26,27]. PCSK9 is also associated with multiple meta-
bolic markers, including fasting insulinemia and high-density
lipoprotein cholesterol (HDL-C). This suggests a possible role
in the development of mixed dyslipidemia associated with the
metabolic syndrome [22].
4.1. PCSK9 mutations
PCSK9 mutations represent the major source of variability in
PCSK9 expression. Two types of PCSK9 mutations with
opposing effects on plasma levels of LDL-C have been identi-
ﬁed: gain of function and loss of function mutations (Table 1).
Table 1 Summary of the effects of PCSK9 variants
Type of variant Example Eﬀect on LDL-C levels Eﬀect on cardiovascular risk
Gain of function E670G › Increased risk
Loss of function C679X (African Americans) R46L (Caucasians) ﬂ Cardioprotective
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Figure 1 In the Lipoprotein Coronary Atherosclerosis Study (n= 372), individuals with both copies of the E607G PCSK9 gain of
function variant (GG) had signiﬁcantly higher mean LDL-C levels and greater severity of coronary stenosis than those with one (E/G) or
no copies (EE). Data from Chen et al. [13].
P=0.008
No       Yes
PCSK9142X, PCSK9679X 
variants
C
or
on
ar
y 
H
ea
rt 
D
is
ea
se
 (%
) 12
8
4
0
No Mutation (n=3,278)
Fr
eq
ue
nc
y 
(%
) 
30
20
10
0
30
20
10
0
0     50   100  150  200  250  300
50th Percentile
Plasma LDL-C (mg/dL)
PCSK9Y142X or PCSK9C679X (n=85)
0     50   100  150  200  250  300
28% ↓ in LDL-C
88% ↓ in CHD
Figure 2 Loss of function PCSK9 variants (Y142X or C679X) in African Americans were associated with signiﬁcant reduction in LDL-
C levels and coronary heart disease (CHD) incidence. Data from Cohen et al. [30].
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As previously discussed (see Section 3), gain of function
PCSK9 variants lead to lower LDL-R levels and in turn higher
levels of LDL-C. The severity of the associated hypercholester-
olemia depends on the site of the mutation. When more than
one mutation is present, it is likely that these deleterious effects
are additive. Studies estimate that PCSK9 gain of function
mutations account for 2–3% of all autosomal-dominant
cases of FH [28].
As a result of elevated LDL-C levels, individuals with gain
of function PCSK9 variants are also at increased risk of prema-
ture cardiovascular disease (Fig. 1). Genotype testing of a co-
hort (n= 372) from the Lipoprotein Coronary
Atherosclerosis Study [13] identiﬁed the E607 PCSK9 gain of
function variant as independently predictive of LDL-C levels.Individuals with both copies of this variant not only had the
highest LDL-C levels (172 mg/dL vs. 147 mg/dL in those with
only one copy), but also increased severity of coronary artery
stenosis. Additionally, data from the Belgium Stroke Study
[24] in 237 patients (and 326 controls) showed that carriers of
the E670G variant (without history of prior stroke) had more
than a three-fold increase in risk of large vessel atherosclerotic
stroke versus those without this variant (odds ratio 3.52,
p= 0.017).
4.1.2. Loss of function mutations
Loss of function PCSK9 variants have also been identiﬁed as
having the opposite effect on PCSK9 expression and circulat-
ing levels of LDL-C. These variants are more prevalent in cer-
tain ethnic groups, in particular those of African American
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J.-C. Fruchart 7descent. Studies indicate that about 2–3% of African
American subjects may have one of these variants (either
Y142X or C679X), and as a consequence, substantially lower
LDL-C levels than in those without these variants [29,30]. This
suggests the possibility that loss-of-function PCSK9 mutations
might be protective against cardiovascular disease, supported
by cross-sectional data. In the Atherosclerosis Risk in Com-
munities Study (ARIC), African Americans with missense
PCSK9 variants (either Y142X or C679X) had 28% lower
mean LDL-C levels (p= 0.008), which were associated with
an 88% reduction in coronary events (hazard ratio 0.11,
p= 0.03) (Fig. 2). Caucasian subjects with the R46L variant
had a 50% reduction in coronary events, despite a mean reduc-
tion in LDL-C of only 15% [30]. Additionally, the prevalence
of peripheral artery disease was 50% lower in carriers of these
PCSK9 loss of function variants [31].
Moreover, there is evidence of longitudinal association of
PCSK9 loss of function variants with reduced subclinical car-
diovascular burden. Data from the Coronary Artery Risk
Development in Young Adults Study [32] showed that subjects
with PCSK9 loss of function variants (L25SF, C679X and
Y142X) had lower LDL-C levels at age 18 years, compared
with non-carriers, and this difference widened over time.
Long-term reduction in LDL-C levels was also associated with
lower carotid intima-media thickness and lower prevalence of
coronary calciﬁcation at later ages (38–50 years).
4.2. Lipid-modifying treatment
4.2.1. Statins
Statins up-regulate LDL-R expression, increasing LDL clear-
ance and subsequently lowering LDL-C levels. Experimental
studies have shown that statins also increase PCSK9 mRNA
expression via activation of the SREBP-2 pathway, which
would be expected to have the opposite effect, exerting a break
on LDL-C lowering efﬁciency [5]. This is supported by the evi-
dence that mice deﬁcient in PCSK9 show an enhanced LDL-C
response to statin treatment [33]. Furthermore, individuals
with loss of function PCSK9 variants (R46L, G106R,
N157K, and R237W) also exhibited greater LDL-C reductions
with statin therapy [34].
Clinically, the LDL-C lowering efﬁcacy of the statin is
dependent on the net effect of these two opposing pathways
[35]. Studies showed that treatment with a statin (atorvastatin,
rosuvastatin, simvastatin and pravastatin) increased plasma
PCSK9 levels [21,36]. This effect was dose-dependent and cor-
related with the extent of LDL-C reduction. Co-administration
of ezetimibe and a statin further increased plasma PCSK9 lev-
els, an effect attributed to reduced breakdown rather than en-
hanced secretion of PCSK9 (Fig. 3) [21].
4.2.2. Fibrates
In clinical practice, ﬁbrates are usually prescribed to treat hyper-
triglyceridemia and low HDL-C, via PPARa-mediated mecha-
nisms involving upregulation of the production and secretion
ofHDL and reduction of very-low-density lipoprotein triglycer-
ide secretion [37]. Recent evidence also indicates that ﬁbrates
modulate plasma PCSK9 levels [25–27]. In a cohort of 115 pa-
tients with type 2 diabetes from the FIELD study, treatment
with fenoﬁbrate (200 mg/day for 6 weeks) decreased plasma lev-
els of PCSK9 by 8.5%. This decrease correlated with the changein plasma levels of LDL-C, suggesting that PCSK9 repression
may partly explain the LDL-C lowering effects of fenoﬁbrate
[25]. Results were more variable in another study, in which plas-
ma PCSK9 levels were both increased and decreased after treat-
ment with either fenoﬁbrate or gemﬁbrozil in 19 individuals
(overall increase of 17.0%) [27].
Cell culture studies show that the PPARa agonist fenoﬁ-
brate reduces PCSK9 mRNA and protein expression in hepa-
tocytes obtained from wild-type mice but not in those from
mice deﬁcient in PPARa [38]. Subsequently, Kourimate et al.
[6] demonstrated that PPARa agonists, including Wy14643,
gemﬁbrozil, cloﬁbrate or fenoﬁbric acid (the active form of
fenoﬁbrate) repressed PCSK9 expression in human immortal-
ized hepatocytes. For fenoﬁbric acid, there was dose-depen-
dent repression of PCSK9 over the range of 100–250 lM.
Additionally, fenoﬁbric acid increased PC5 and furin expres-
sion, the latter in a dose-dependent manner. These enzymes
cleave lipoprotein lipase (triglyceride lipase) and degrade phos-
pholipase endothelial lipase, which is responsible for mediating
the hydrolysis of phospholipids from HDL, as well as conver-
sion of large LDL to LDL with lower afﬁnity for the LDL-R.
Together, these data suggest a dual mechanism mediated via
PPARa for repression of PCSK9 at the transcriptional level,
targeting both mRNA synthesis and protein degradation
(Fig. 4). Fibrates also promote a remodelling of LDLs, reduc-
ing the number of dense proatherogenic particles and increas-
ing the number of large LDLs with increased binding capacity
for the LDL-R [39]. Clinically, these actions translate to higher
circulating levels of HDL-C and lower levels of LDL-C. These
experimental data, together with limited LDL-C lowering efﬁ-
cacy observed in clinical studies such as the FIELD study [40],
suggest the existence of a negative feedback pathway similar to
PCSK9 upregulation by statins. This warrants further study.
Evidence suggests that fenoﬁbrate may modulate the up-
regulation of PCSK9 associated with statin therapy. In sup-
port of this, in vitro studies showed that addition of fenoﬁbric
acid or pravastatin increased the binding of 125I-LDL to LDL-
R in human hepatocytes versus control. When co-administered
with pravastatin, fenoﬁbric acid counteracted the statin-in-
duced expression of PCSK9 leading to a further 30% increase
in LDL-R activity over pravastatin alone [6]. Clinically, the
combination of fenoﬁbrate plus statin has been shown to
Figure 4 Proposed dual mechanism for ﬁbrate mediated repression of PCSK9 to increase LDL clearance and increase circulating levels
of HDL-C. Reproduced with permission from Kourimate et al. [6].
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with statin alone [41]. These data, therefore, provide a func-
tional rationale for the combination of fenoﬁbrate with a statin
for optimizing LDL-C lowering efﬁcacy.
4.3. Other agents
Several other agents are also known to inhibit PCSK9 expres-
sion. These include berberine, a natural plant extract [42] and
small interfering RNAs (siRNAs) capable of targeting PCSK9
[43]. In vitro studies showed that berberine in combination
with mevastatin increased LDL-R and protein levels, while
at the same time repressing the increase in PCSK9 mRNA lev-
els with mevastatin alone [42]. We await future work to evalu-
ate whether such agents may have an application as a
supplement to statin treatment.
5. Clinical implications
Dyslipidemia is clearly established as one of the most impor-
tant modiﬁable risk factors for cardiovascular disease, with
lowering of LDL-C with statin therapy a management priority
[44]. Yet even among those patients who achieve LDL-C goals,
the residual risk of further cardiovascular events remains unac-
ceptably high [45–47].
Elucidation of the mode of action of PCSK9 as an inhibitor
of LDL-R activity presents new therapeutic possibilities, not
only for PCSK9 as a therapeutic target, but also for the func-
tional relevance of adding a PPARa agonist such as fenoﬁ-
brate to amplify the LDL-C lowering efﬁcacy of a statin.
Finally, evidence that PCSK9 levels are correlated with plasma
levels of glucose, triglycerides and HDL-C suggests that
PCSK9 may be a potential target in subjects with type 2 diabe-
tes or metabolic syndrome.The recently reported Action to Control Cardiovascular
Risk (ACCORD) Lipid Study is the ﬁrst outcome study to
have tested the therapeutic approach of adding fenoﬁbrate to
statin therapy in type 2 diabetes patients, to reduce residual
cardiovascular risk [48]. In the total study population, this
combination treatment did not signiﬁcantly impact any of
the study outcomes; however, in the subgroup of patients with
baseline triglycerides in the upper third (P204 mg/dL) and
baseline HDL-C in the lower third (634 mg/dL) there was evi-
dence suggestive of additional beneﬁt with fenoﬁbrate (31%
lowering of major cardiovascular events, the primary end-
point). It would be of interest to know whether fenoﬁbrate also
prevented the upregulation of PCSK9 expression by simvasta-
tin in these patients.
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